Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Advanced Bronchioalveolar Cell Lung Cancer
NCT00416650Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jul 2002
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in bronchioloalveolar carcinoma (BAC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Major Objective Response Rate. Started Jul 2002; status: completed.
02
Drugs
erlotinib
03
Conditions
bronchioloalveolar carcinoma (BAC)
Beyond the preview
Go deeper on NCT00416650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00416650.